Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Interleukin-12 receptor is a heterodimeric type I cytokine receptor composed of two subunits, IL-12Rβ1 and IL-12Rβ2, mainly expressed on T cells and natural killer cells. This receptor binds interleukin-12, a heterodimeric cytokine composed of p35 and p40 subunits, triggering activation of JAK2/TYK2 kinases and STAT4 signaling. IL-12 receptor engagement promotes Th1 differentiation, cytotoxic activity, and interferon-gamma production, playing a critical role in mediating the pro-inflammatory immune response and bridging innate and adaptive immunity. Dysregulation of this pathway is implicated in the pathogenesis of autoimmune and inflammatory diseases, cancer, and infection. Therapeutic agents targeting IL-12 or its shared p40 subunit have shown efficacy in certain inflammatory conditions but may carry risks of immune suppression and infections.
Neutralization of IL-12/IL-23 p40 subunit, blocking IL-12 and IL-23 signaling Inhibition of Th1 and Th17 cell differentiation and associated inflammatory responses
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Interleukin-12 receptor (IL-12R).